,Outcomes,Arm 1,Arm 2
0,intervention,Capecitabine/docetaxel,docetaxel
1,time to disease progression ( TTP ),6.1,4.2
2,objective tumor response rate,42 %,30 %
3,overall survival,14.5,11.5
